Clinical Reach Platform, a Product of Parallel 6, is a Solution that Powers Multi-Site, Multi-Language, and Multi-Country Clinical Trials Through Patient Enrollment and Engagement Technologies

By June 11, 2015Press Releases

FOR IMMEDIATE RELEASE

Contact:

Nikki Jimenez

nikki.jimenez@focuscominc.com

619-233-7778

 

Clinical Reach Platform, a Product of Parallel 6, is a Solution that Powers Multi-Site, Multi-Language, and Multi-Country Clinical Trials Through Patient Enrollment and Engagement Technologies 

Parallel 6 signs multiple clinical trials in 2015 with large Biopharma, Institutes and other stakeholders

 

SAN DIEGO (June 11, 2015)Parallel 6, an innovator in enterprise mobile engagement and management solutions, is pleased to announce that its complete mobile clinical trial management and engagement platform, Clinical Reach, is now powering multiple clinical trials in 2015.clinical trials

Clinical Reach’s patient enrollment and engagement solution is helping some of the industry’s top Biopharma, Institutes and other stakeholders to more efficiently enroll and quickly connect with participants when and where it matters most, in the palm of the participant’s hand. The platform allows investigators to manage and monitor an entire trial in real-time, with multi-site, multi-language, and multi-country capabilities – ultimately identifying areas of risk in real-time.

“Throughout the course of a clinical trial, which can last up to 5+ years, we understand that participants go through significant life events, which can lead to them dropping out of a clinical trial,” said Parallel 6 President & CTO, Founder, David Turner. “In those critical moments where clinical trial participants may not want to go to an appointment, or forget to take their scheduled medication, is when the Clinical Reach platform can connect them with their physicians or investigators when it matters most, to keep them engaged.”

As Parallel 6 continues to work with respected CRO’s, sponsors and stakeholders across the nation, Parallel 6 is making the clinical trial process easier and more efficient to save time and money.

“It’s our goal to innovate the best technology for clinical trials and get the needed drugs to the right people faster,” said Parallel 6 CEO, Allan Camaisa. “We’re honored to work on diverse clinical trials around the world and our leadership team will continue to be driven by the fact that our technology can improve lives.”

Clinical Reach is a patented technology and is 21 CFR Part 11/EU Annex 11 Compliant. Its platform connects to all mobile technologies including wearables, phones, in-car systems, displays and other patient centric devices.

Parallel 6 is an exhibitor at the DIA 2015 51st Annual Meeting gathering in Washington, D.C. Booth #1957. Parallel 6 CEO and Chairman, Allan Camaisa and President, CTO and Founder, David Turner, will be available for interviews and a demo of their technology platform. Please contact: Nikki Jimenez – nikki.jimenez@focuscominc.com – 619-233-7778 to schedule a briefing, demo and/or interview.

###

About Parallel 6

Parallel 6, an innovator in enterprise cloud-based technologies, enables customer engagement and real-time data insights. Clinical Reach, a Parallel 6 product, enables clinical trial stakeholders to digitally recruit, eQualify, eConsent and engage clinical trial participants through their patented platform. Additional solutions include GovReach for Government Agencies and Captive Reach for corporate organizations which desire to communicate via push notifications, gamification strategies and more. The firm is headquartered in San Diego with Federal offices in Washington D.C. For more information, visit http://http://www.parallel6.com/.

About Liz Rogers